InfraVia Growth invests in Orakl Oncology to make cancer drug response predictable before clinical trials
The Series A, co-led by Norrsken VC and Singular, follows a breakthrough: Orakl's AI predicted cancer clinical trial outcomes prospectively with 90% accuracy.
WeAreBlow12 November 2026








